<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer - Sathianathen, NJ - 2020 | Cochrane Library</title> <meta content="Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer - Sathianathen, NJ - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013245.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer - Sathianathen, NJ - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013245.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013245.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer" name="citation_title"/> <meta content="Niranjan J Sathianathen" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="niranjan19@gmail.com" name="citation_author_email"/> <meta content="Makinna C Oestreich" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Sarah Jane Brown" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Shilpa Gupta" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Badrinath R Konety" name="citation_author"/> <meta content="University of Minnesota" name="citation_author_institution"/> <meta content="Philipp Dahm" name="citation_author"/> <meta content="Minneapolis VA Health Care System" name="citation_author_institution"/> <meta content="Frank Kunath" name="citation_author"/> <meta content="University Hospital Erlangen" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD013245.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/12/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013245.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013245.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013245.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Abiraterone Acetate [adverse effects, *therapeutic use]; Androgen Antagonists [adverse effects, *therapeutic use]; Antineoplastic Agents, Hormonal [*therapeutic use]; Disease Progression; Neoplasm Grading; Prostatic Neoplasms [*drug therapy, mortality, pathology]; Quality of Life; Randomized Controlled Trials as Topic; Withholding Treatment [statistics &amp; numerical data]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013245.pub2&amp;doi=10.1002/14651858.CD013245.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="gpg7sF9V";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013245\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013245\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013245.pub2",title:"Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone\\u2010sensitive prostate cancer",firstPublishedDate:"Dec 12, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Urology Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=gpg7sF9V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013245.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013245.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013245.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013245.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013245.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013245.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013245.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013245.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013245.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013245.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4797 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013245.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0046"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-sec-0084"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/appendices#CD013245-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/supinfo/CD013245StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/supinfo/CD013245StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Niranjan J Sathianathen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0005">Makinna C Oestreich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0006">Sarah Jane Brown</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0007">Shilpa Gupta</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0008">Badrinath R Konety</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0009">Philipp Dahm</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information#CD013245-cr-0010">Frank Kunath</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information/en#CD013245-sec-0105">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 December 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013245.pub2">https://doi.org/10.1002/14651858.CD013245.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013245-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013245-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013245-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013245-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013245-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD013245-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013245-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013245-abs-0001" lang="en"> <section id="CD013245-sec-0001"> <h3 class="title" id="CD013245-sec-0001">Background</h3> <p>Systemic androgen deprivation therapy (ADT), also referred to as hormone therapy, has long been the primary treatment for metastatic prostate cancer. Additional agents have been reserved for the castrate‐resistant disease stage when ADT start becoming less effective. Abiraterone is an agent with an established role in that disease stage, which has only recently been evaluated in the hormone‐sensitive setting. </p> </section> <section id="CD013245-sec-0002"> <h3 class="title" id="CD013245-sec-0002">Objectives</h3> <p>To assess the effects of early abiraterone acetate, in combination with systemic ADT, for newly diagnosed metastatic hormone‐sensitive prostate cancer. </p> </section> <section id="CD013245-sec-0003"> <h3 class="title" id="CD013245-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, Embase, six other databases, two trials registries, grey literature, and conference proceedings, up to 15 May 2020. We applied no restrictions on publication language or status. </p> </section> <section id="CD013245-sec-0004"> <h3 class="title" id="CD013245-sec-0004">Selection criteria</h3> <p>We included randomized trials, in which men diagnosed with hormone‐sensitive prostate cancer were administered abiraterone acetate and prednisolone with ADT or ADT alone. </p> </section> <section id="CD013245-sec-0005"> <h3 class="title" id="CD013245-sec-0005">Data collection and analysis</h3> <p>Two review authors independently classified studies and abstracted data from the included studies. We performed statistical analyses<br/>using a random‐effects model. We rated the quality of evidence according to the GRADE approach. </p> </section> <section id="CD013245-sec-0006"> <h3 class="title" id="CD013245-sec-0006">Main results</h3> <p>The search identified two randomized controlled trials (RCT), with 2201 men, who were assigned to receive either abiraterone acetate 1000 mg once daily and low dose prednisone (5mg) in addition to ADT, or ADT alone. In the LATITUDE trial, the median age and range of men in the intervention group was 68 (38 to 89) years, and 67 (33 to 92) years in the control group. Nearly all of the men in this study (97.6%) had prostate cancer with a Gleason score of at least 8 (ISUP grade group 4). </p> <p><b>Primary outcomes</b> </p> <p>The addition of abiraterone acetate to ADT reduces the probability of death from any cause compared to ADT alone (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.56 to 0.73; 2 RCTs, 2201 men; high certainty of evidence); this corresponds to 163 fewer deaths per 1000 men with hormone‐sensitive metastatic prostate cancer (210 fewer to 115 fewer) at five years. </p> <p>Abiraterone acetate in addition to ADT probably results in little to no difference in quality of life compared to ADT alone, measured with the Functional Assessment of Cancer Therapy‐prostate total score (FACT‐P; range 0 to 156; higher values indicates better quality of life), at 12 months (mean difference [MD] 2.90 points, 95% CI 0.11 to 5.60; 1 RCT, 838 men; moderate certainty of evidence). </p> <p><b>Secondary outcomes</b> </p> <p>Abiraterone plus ADT increases the risk of grades III to V adverse events compared to ADT alone (risk ratio [RR] 1.34, 95% CI 1.22 to 1.47; 1 RCT, 1199 men; high certainty of evidence); this corresponds to 162 more grade III to V events per 1000 men with hormone‐sensitive metastatic prostate cancer (105 more to 224 more) at a median follow‐up of 30 months. </p> <p>Abiraterone acetate in addition to ADT probably reduces the probability of death due to prostate cancer compared to ADT alone (HR 0.58, 95% CI 0.50 to 0.68; 2 RCTs, 2201 men; moderate certainty of evidence). This corresponds to 120 fewer death from prostate cancer per 1000 men with hormone‐sensitive metastatic prostate cancer (95% CI 145 fewer to 90 fewer) after a median follow‐up of 30 months. </p> <p>The addition of abiraterone acetate to ADT probably decreases the probability of disease progression compared to ADT alone (HR 0.35, 95%CI 0.26 to 0.49; 2 RCTs, 2097 men; moderate certainty of evidence). This corresponds to 369 fewer incidences of disease progression per 1000 men with hormone‐sensitive metastatic prostate cancer (456 fewer to 256 fewer) after a median follow‐up of 30 months. </p> <p>The addition of abiraterone acetate to ADT probably increases the risk of discontinuing treatment due to adverse events compared to ADT alone (RR 1.50, 95% CI 1.17 to 1.92; 1 RCT, 1199 men; moderate certainty of evidence). This corresponds to 51 more men (95% CI 17 more to 93 more) discontinuing treatment because of adverse events per 1000 men treated with abiraterone acetate and ADT compared to ADT alone after a median follow‐up of 30 months. </p> </section> <section id="CD013245-sec-0007"> <h3 class="title" id="CD013245-sec-0007">Authors' conclusions</h3> <p>The addition of abiraterone acetate to androgen deprivation therapy improves overall survival but probably not quality of life. It probably also extends disease‐specific survival, and delays disease progression compared to androgen deprivation therapy alone. However, the risk of grades III to V adverse events is increased, and probably, so is the risk of discontinuing treatment due to adverse events. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013245-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013245-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013245-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013245-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013245-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD013245-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013245-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/th#CD013245-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD013245-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013245-abs-0002" lang="en"> <h3>Adding abiraterone acetate to androgen deprivation therapy for the treatment of metastatic hormone‐sensitive prostate cancer </h3> <p><b>Review question</b> </p> <p>The aim of this review was to find out what the effect of adding abiraterone was, in men with prostate cancer, who were receiving and still responding to hormone therapy. </p> <p><b>Background</b> </p> <p>Abiraterone acetate is a medication that blocks the effect of male sex hormones, and thereby, slows down prostate cancer growth.  </p> <p>More than 15% of men diagnosed with prostate cancer present with disease that has spread beyond the prostate. Another 15% to 30% of men who undergo primary treatment will experience a return of their cancer. Hormone therapy (drugs to reduce the level of male hormones) has been the main treatment for advanced disease, but this does not work forever. Recent studies have looked at whether drugs that block the growth of prostate cancer cells, such as abiraterone acetate, can improve how men do. </p> <p><b>Study characteristics</b> </p> <p>We found two studies (specifically, studies in which 'chance' decided what treatment men got), with a total of 2201 men. The studies compared abiraterone acetate and hormone therapy to hormone therapy alone. In one of the studies, most of the included men had high risk prostate cancer, and had previously undergone local treatment. In the other study, most men had not had previous treatment to their prostate. The evidence is current to 15 May 2020. </p> <p><b>Key results</b> </p> <p>Adding abiraterone acetate to hormone therapy improves overall survival but probably not quality of life. It probably improves cancer‐specific survival and reduces disease progression. However, there is also an increase in severe and life‐threatening side effects, likely leading to discontinued treatment, with the addition of abiraterone acetate. </p> <p><b>Quality of the evidence</b> </p> <p>We judged the certainty of the evidence to be high for overall survival (time to death from any cause), and severe and life‐threatening side effects. This means that our estimates are likely to be close to the actual effect for these outcomes. The certainty of the evidence was moderate for quality of life, cancer‐specific survival (time to death from prostate cancer), time to disease progression, and discontinued treatment due to adverse events. This means that our estimates are likely to be close to the actual effect, but there were some limitations in the studies that reduced our confidence in the results. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013245-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013245-sec-0090"></div> <h3 class="title" id="CD013245-sec-0091">Implications for practice</h3> <section id="CD013245-sec-0091"> <p>The addition of abiraterone acetate with prednisolone to androgen deprivation therapy improves overall survival, and probably extends disease‐specific survival and delays progression, compared to androgen deprivation therapy alone. It also results in a small improvement in quality of life at 12 months, but this is not clinically meaningful. However, grades III to V adverse events are increased, and probably more men discontinue treatment because of them. Therefore, men should be counseled about adverse events before commencing treatment, to help them understand the trade‐offs of treatment. </p> </section> <h3 class="title" id="CD013245-sec-0092">Implications for research</h3> <section id="CD013245-sec-0092"> <p>Given our inability to conduct all of the pre‐specified subgroup analyses, further research is required to define treatment effects across potential prognostic clinical characteristics, such as the volume of disease and prior treatment to the prostate. This would assist in identifying which men are more likely to experience the greatest benefit from upfront combination treatment with abiraterone acetate and ADT. The increasing use of prostate‐specific membrane antigen‐positron emission tomography (PSMA‐PET) imaging globally warrants research in this setting, as it may impact classification in terms of volume of disease, and subsequently selection of men more likely to benefit. </p> <p>Recently, there have been other agents that have been shown to be superior to ADT alone, to treat hormone‐sensitive metastatic prostate cancer (<a href="./references#CD013245-bbs2-0010" title="ChiKM , AgarwalN , BjartellA , ChungBH , Pereira de Santana GomesAJ , GivenR , et al. Apalutamide for metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2019;381:13-24.">Chi 2019</a>; <a href="./references#CD013245-bbs2-0011" title="DavisID , MartinAJ , StocklerMR , BegbieS , KimKN , ChowdhuryS , et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine2019;381:121-31.">Davis 2019</a>). Clinicians are currently relying predominantly on indirect evidence in deciding between these agents, but these estimates are not a substitute for direct evidence (<a href="./references#CD013245-bbs2-0045" title="SathianathenNJ , KoschelS , ThangasamyIA , TehJ , AlghazoO , ButcherG , et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. European Urology2019;77(3):365-72. [DOI: 10.1016/j.eururo.2019.09.004] [PMID: 31679970]">Sathianathen 2019</a>). Therefore, we need high quality head to head studies to determine which combination of treatment, if any, is superior to the others. Similarly, since multiple agents have demonstrated improvements over ADT alone in men with hormone sensitive prostate cancer, the cost of these agents should be considered when deciding which to use, especially in low‐income settings (<a href="./references#CD013245-bbs2-0046" title="SathianathenNJ , Alarid-EscuderoF , KuntzKM , LawrentschukN , BoltonDM , Kim SP et al. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. European Urology Oncology2019;2(6):649-55.">Sathianathen 2019a</a>). Along these lines, additional research is required to identify the optimal sequence of treatment following progression, because there is evidence that shows that responsiveness to treatment following progression is dependent on previous exposure.  </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013245-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013245-sec-0008"></div> <div class="table" id="CD013245-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with metastatic, hormone‐sensitive prostate cancer<br/><b>Setting:</b> outpatient; multinational sites across UK, Europe, the Asia–Pacific region, Latin America, and Canada<br/><b>Intervention:</b> abiraterone + androgen deprivation therapy (ADT)<br/><b>Comparison:</b> ADT alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ADT only</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with abiraterone + ADT</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to death from any cause</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2201<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.64<br/>(0.56 to 0.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>General population<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>702 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 fewer per 1000<br/>(210 fewer to 115 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>(Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life])</i> </p> <p><i>measured at 12 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>838 (1 RCT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life for men on ADT only was 116 points</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The MD for men on abiraterone + ADT was 2.9 points higher (0.11 higher to 5.69 higher)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Grades III to V adverse events</b> </p> <p><i>(severe and life threatening, as per the Common Toxicity Criteria v3.0; )</i> </p> <p><i>measured at a median follow‐up of 30 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1199<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/>(1.22 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 more per 1000<br/>(105 more to 224 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to death due to prostate cancer</b> </p> <p><i>measured at a median follow‐up of 30.4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2201<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.58<br/>(0.50 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 fewer per 1000<br/>(145 fewer to 90 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to disease progression</b> </p> <p><i>measured at a median follow‐up of 30 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2097<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.35<br/>(0.26 to 0.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>785 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369 fewer per 1000<br/>(456 fewer to 256 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Discontinued treatment due to adverse events</b> </p> <p><i>measured at a median follow‐up of 30 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1199<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/>(1.17 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 more per 1000<br/>(17 more to 93 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR</b> : hazard ratio; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Population data from SEER registry, prostate cancer stage IV 5‐year survival (70.2%) in the pre‐docetaxel era (2007 to 2013)<br/><sup>b</sup>Certainty of evidence graded down by one level due to concerns regarding study limitations related to attrition bias<br/><sup>c</sup>Baseline risk for grades III to V adverse events, prostate cancer‐specific death, and discontinued treatment due to adverse events calculated from the control arm of the LATITUDE trial at a median of 30 months follow‐up (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>)<br/><sup>d</sup>Certainty of evidence downgraded by one level due to study limitations<br/><sup>e</sup>Baseline progression risk calculated from control arm of STAMPEDE trial at 3 years (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>) </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013245-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013245-sec-0009"></div> <section id="CD013245-sec-0010"> <h3 class="title" id="CD013245-sec-0010">Description of the condition</h3> <p>Prostate cancer is the most frequently diagnosed cancer amongst men in high‐income countries, and causes over 300,000 deaths worldwide every year (<a href="./references#CD013245-bbs2-0055" title="TorreLA , BrayF , SiegelRL , FerlayJ , Lortet-TieulentJ , JemalA . Global cancer statistics, 2012. CA: a Cancer Journal for Clinicians2015;65(2):87-108.">Torre 2015</a>). In the USA, prostate cancer accounts for one in five new diagnoses of all cancers, and is the second leading cause of cancer death amongst men (<a href="./references#CD013245-bbs2-0050" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2018. CA: a Cancer Journal for Clinicians2018;68(1):7-30.">Siegel 2018</a>). Most prostate cancers tend to be localized at the time of diagnosis, and are managed with active monitoring and surveillance, radical surgery, or radiation therapy (<a href="./references#CD013245-bbs2-0021" title="HamdyFC , DonovanJL , LaneJA , MasonM , MetcalfeC , HoldingP , et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. New England Journal of Medicine2016;375(15):1415-24.">Hamdy 2016</a>). A subgroup of these men experience local or distant disease recurrence after local therapy. The estimated eight‐year risk of metastases following radical prostatectomy is 3%, and following external beam radiation therapy is 7% (<a href="./references#CD013245-bbs2-0058" title="ZelefskyMJ , EasthamJA , CroninAM , Fuks Zi, ZhangZ , YamadaY , et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. Journal of Clinical Oncology2010;28(9):1508-13.">Zelefsky 2010</a>). Approximately 16% of men present with regional or distant‐stage disease at the time of initial diagnosis (<a href="./references#CD013245-bbs2-0050" title="SiegelRL , MillerKD , JemalA . Cancer statistics, 2018. CA: a Cancer Journal for Clinicians2018;68(1):7-30.">Siegel 2018</a>). Therefore, the burden of advanced prostate cancer is considerable. </p> <p>Since Huggins and colleagues discovered the androgen‐dependent nature of prostate cancer, androgen deprivation therapy has underpinned the management of locally advanced and metastatic hormone‐sensitive prostate cancer (<a href="./references#CD013245-bbs2-0027" title="HugginsC , Stevens RE Jr, Hodges CV . Studies on prostatic cancer: Ii. the effects of castration on advanced carcinoma of the prostate gland. Archives of Surgery1941;43(2):209-23.">Huggins 1941</a>). Although androgen deprivation therapy demonstrates antitumor activity with marked reduction of the prostate‐specific antigen (PSA) in the majority of men, it is not curative. Most men eventually experience progression of their cancer despite ongoing hormone treatment, which is a lethal disease state, referred to as castration‐resistant prostate cancer. This progression occurs after a mean of 11 months on androgen deprivation therapy (<a href="./references#CD013245-bbs2-0029" title="JamesND , SpearsMR , ClarkeNW , DearnaleyDP , De BonoJS , GaleJ , et al. Survival with newly diagnosed metastatic prostate cancer in the “Docetaxel Era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). European Urology2015;67(6):1028-38.">James 2015</a>). The mechanisms involved in the progression of disease are not entirely understood, and are currently thought to be a multifactorial process that facilitates androgen receptor activity through amplification, mutations, splice variants, and aberrant activation (<a href="./references#CD013245-bbs2-0054" title="TilkiD , SchaefferEM , EvansCP . Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor. European Urology Focus2016;2(5):499-505.">Tilki 2016</a>). Once in this resistant state, men face a poor prognosis, with a pooled median survival of 16 to 30 months (<a href="./references#CD013245-bbs2-0053" title="TannockIF , deWitR , BerryWR , HortiJ , PluzanskaA , ChiKN , et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine2004;351(15):1502-12.">Tannock 2004</a>; <a href="./references#CD013245-bbs2-0007" title="BeerTM , ArmstrongAJ , RathkopfDE , LoriotY , SternbergCN , HiganoCS , et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine2014;371(5):424-33.">Beer 2014</a>; <a href="./references#CD013245-bbs2-0041" title="RyanCJ , SmithMR , FizaziK , SaadF , MuldersPF , SternbergCN , et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology2015;16(2):152-60.">Ryan 2015</a>). Castration‐resistant disease is also associated with considerable morbidity and a negative impact on quality of life. It has been reported that 45% of men experienced bone pain at the time of diagnosis, and 80% of men experienced bone pain at a mean follow‐up of 18 months (<a href="./references#CD013245-bbs2-0028" title="InoueT , SegawaT , KambaT , YoshimuraK , NakamuraE , NishiyamaH , et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology2009;73(5):1104-9.">Inoue 2009</a>). Increased incidence of major skeletal events, such as vertebral collapse, fractures, and spinal cord compression, also occur with disease progression (<a href="./references#CD013245-bbs2-0008" title="BerrutiA , TucciM , MoscaA , TarabuzziR , GorzegnoG , TerroneC , et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. British Journal of Cancer2005;93(6):633-8.">Berruti 2005</a>). </p> <p>The landscape of advanced prostate cancer treatment has undergone considerable transformation since the early 2000s, prior to which no treatment had been shown to confer a survival benefit. Early randomised trials, examining the role of chemohormonal therapy using chemotherapeutic agents, such as epirubicin (<a href="./references#CD013245-bbs2-0037" title="PummerK , LehnertM , StettnerH , HubmerG . Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. European Urology1997;32 Suppl 3:81-5.">Pummer 1997</a>), estramustine (<a href="./references#CD013245-bbs2-0031" title="JanknegtRA , BoonTA , vande BeekC , GrobP . Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology1997;49(3):411-20.">Janknegt 1997</a>), cyclophosphamide (<a href="./references#CD013245-bbs2-0035" title="MurphyGP , BeckleyS , BradyMF , Ming ChuT , DekernionJB , DhabuwalaC , et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer1983;51(7):1264-72.">Murphy 1983</a>), or a combination of ketoconazole plus doxorubicin alternating with vinblastine plus estramustine, demonstrated no improvement in survival (<a href="./references#CD013245-bbs2-0034" title="MillikanRE , WenS , PagliaroLC , BrownMA , MoomeyB , DoKA , et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. Journal of Clinical Oncology2008;26(36):5936-42.">Millikan 2008</a>). However, there was a landmark discovery in 2004, when two studies reported prolonged overall survival in men with metastatic castration‐resistant cancer who received docetaxel (<a href="./references#CD013245-bbs2-0036" title="PetrylakDP , TangenCM , HussainMH , Lara PN Jr, JonesJA , TaplinME , et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. New England Journal of Medicine2004;351(15):1513-20.">Petrylak 2004</a>; <a href="./references#CD013245-bbs2-0053" title="TannockIF , deWitR , BerryWR , HortiJ , PluzanskaA , ChiKN , et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New England Journal of Medicine2004;351(15):1502-12.">Tannock 2004</a>). Since the US Food and Drug Administration approval for the use of docetaxel in metastatic disease, a number of other agents have entered the market, such as abiraterone acetate (<a href="./references#CD013245-bbs2-0013" title="deBonoJS , LogothetisCJ , MolinaA , FizaziK , NorthS , ChuL , et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine2011;364(21):1995-2005.">de Bono 2011</a>; <a href="./references#CD013245-bbs2-0041" title="RyanCJ , SmithMR , FizaziK , SaadF , MuldersPF , SternbergCN , et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology2015;16(2):152-60.">Ryan 2015</a>), enzalutamide (<a href="./references#CD013245-bbs2-0048" title="ScherHI , FizaziK , SaadF , TaplinME , SternbergCN , MillerK , et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine2012;367(13):1187-97.">Scher 2012</a>; <a href="./references#CD013245-bbs2-0007" title="BeerTM , ArmstrongAJ , RathkopfDE , LoriotY , SternbergCN , HiganoCS , et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine2014;371(5):424-33.">Beer 2014</a>), cabazitaxel (<a href="./references#CD013245-bbs2-0012" title="deBonoJS , OudardS , OzgurogluM , HansenS , MachielsJP , KocakI , et al, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet2010;376(9747):1147-54.">de Bono 2010</a>), and the therapeutic vaccine sipuleucel‐T (<a href="./references#CD013245-bbs2-0032" title="KantoffPW , HiganoCS , ShoreND , BergerER , SmallEJ , PensonDF , et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New England Journal of Medicine2010;363(5):411-22.">Kantoff 2010</a>). The seminal findings with docetaxel laid the foundation to revisit the concept of upfront chemohormonal therapy, using these newer agents to potentially delay the progression of androgen‐dependent disease to its lethal castration‐resistant form. The newer drugs all focused on men with castration‐resistant prostate cancer. Following the publication of randomised trials demonstrating a survival benefit, docetaxel was introduced earlier in the disease stage, concomitantly with systemic androgen ablation (<a href="./references#CD013245-bbs2-0052" title="SweeneyCJ , ChenYH , CarducciM , LiuG , JarrardDF , EisenbergerM , et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine2015;373(8):737-46.">Sweeney 2015</a>; <a href="./references#CD013245-bbs2-0030" title="JamesND , SydesMR , ClarkeNW , MasonMD , DearnaleyDP , SpearsMR , et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet2016;387(10024):1163-77.">James 2016</a>). As a result, there has been ongoing interest in using other agents that are currently used in the castration‐resistant setting at an earlier stage of the disease course, such as abiraterone acetate. </p> </section> <section id="CD013245-sec-0011"> <h3 class="title" id="CD013245-sec-0011">Description of the intervention</h3> <p>Abiraterone acetate is an androstane derivative that blocks the activity of the enzyme 17alpha‐monooxygenase (17alpha‐hydrolase/C17,20 lyase complex). It is currently approved for use in metastatic castration‐resistant prostate cancer. It is administered orally, at a dose of 1000 mg daily in combination with prednisone 5 mg. </p> <p>Abiraterone acetate is a pro‐drug that is almost completely converted to abiraterone — the active metabolite — in the liver. It has a mean terminal half‐life of 24 hours, and reaches maximal plasma concentration at a median two hours after administration. In plasma, abiraterone is highly bound to both albumin and a1‐glycoprotein. The drug is metabolized through several hepatic pathways, therefore, hepatic impairment decreases the elimination of abiraterone. It is recommended that the dose of abiraterone is reduced to 250 mg daily for people with moderate hepatic impairment, and is contraindicated in those with severe hepatic impairment. Abiraterone is a substrate of CYP3A4 and SULT2A1, thus, its elimination is effected by other agents that are involved in these pathways, including rifampicin and ketoconazole. </p> <section id="CD013245-sec-0012"> <h4 class="title">Adverse effects of the intervention</h4> <p>Abiraterone is a generally well‐tolerated drug with no dose‐limiting toxicities observed in phase I trials (<a href="./references#CD013245-bbs2-0006" title="AttardG , ReidAH , YapTA , RaynaudF , DowsettM , SettatreeS , et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology2008;26(28):4563-71.">Attard 2008</a>). Most adverse effects are mild to moderate (grades I to II) in nature, and include fatigue, back pain, nausea, constipation, bone pain, hot flashes, diarrhea, and arthralgia (<a href="./references#CD013245-bbs2-0040" title="RyanCJ , SmithMR , deBonoJS , MolinaA , LogothetisCJ , deSouzaP , et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine2013;368(2):138-48.">Ryan 2013</a>). Abiraterone treatment results in a mineralocorticoid excess that can lead to hypertension, hypokalemia, and fluid retention. However, the incidence of these side effects was only 4% for men with grade III, 2% for men with grade IV, and less than 1% in men with chemotherapy‐naïve castration‐resistant prostate cancer (<a href="./references#CD013245-bbs2-0040" title="RyanCJ , SmithMR , deBonoJS , MolinaA , LogothetisCJ , deSouzaP , et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine2013;368(2):138-48.">Ryan 2013</a>). Prednisone is commonly prescribed concomitantly to mitigate these side effects. It was observed that abiraterone acetate treatment led to abnormalities of liver function tests in approximately 11% of men, but these were severe in only 4% (<a href="./references#CD013245-bbs2-0016" title="FizaziK , ScherHI , MolinaA , LogothetisCJ , ChiKN , JonesRJ , et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncology2012;13(10):983-92.">Fizazi 2012</a>; <a href="./references#CD013245-bbs2-0040" title="RyanCJ , SmithMR , deBonoJS , MolinaA , LogothetisCJ , deSouzaP , et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. New England Journal of Medicine2013;368(2):138-48.">Ryan 2013</a>). There was no statistically significant increase in cardiac events with abiraterone treatment compared to placebo in phase III trials in men with castration‐resistant prostate cancer. It should be noted that the aforementioned toxicity data are derived from men with castration‐resistant prostate cancer who are different to the population included in this review, and hence the absolute rates may differ. </p> </section> </section> <section id="CD013245-sec-0013"> <h3 class="title" id="CD013245-sec-0013">How the intervention might work</h3> <p>Abiraterone acetate is a selective irreversible inhibitor of CYP17A (17α‐hydroxylase/17,20‐lyase), which is a cytochrome P450 enzyme that is important in the biosynthesis of androgen. CYP17A is expressed in the adrenal glands, and is involved in the production of adrenal androgens, and facilitates de novo synthesis of androgens by prostate cancer cells. Abiraterone has been demonstrated to directly inhibit androgen receptor activity, including the androgen receptor itself (<a href="./references#CD013245-bbs2-0051" title="SoiferHS , SouleimanianN , WuS , VoskresenskiyAM , CollakFK , CinarB , et al. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells. Journal of Biological Chemistry2012;287(6):3777-87.">Soifer 2012</a>). Because prostate cancer cell growth and survival is largely androgen‐dependent, abiraterone acetate has the potential to delay or inhibit cancer progression by decreasing the production of androgens and blocking androgen receptor activity (<a href="./references#CD013245-bbs2-0022" title="HeinleinCA , ChangC . Androgen receptor in prostate cancer. Endocrine Reviews2004;25(2):276-308.">Heinlein 2004</a>). </p> <p>Administering abiraterone acetate during the early stages of metastatic prostate cancer, rather than waiting for the disease to progress, could be beneficial. Delaying the development of castration‐resistant prostate cancer has important implications. Men are able to maximize their quality of life by delaying the morbidity associated with castration‐resistant disease and the need for further treatment, which has potential adverse events. Since they typically are healthier during the early stages of metastatic prostate cancer, they are more able to withstand the toxicities of treatment. The higher disease burden, and overall decline in functional status experienced with the development of castration‐resistant prostate cancer, will exclude a sizable proportion of men from even receiving abiraterone acetate at this late stage. </p> </section> <section id="CD013245-sec-0014"> <h3 class="title" id="CD013245-sec-0014">Why it is important to do this review</h3> <p>Following the publication of randomized trials that demonstrated a survival benefit for upfront docetaxel with androgen deprivation therapy in metastatic hormone‐sensitive prostate cancer, there has been interest in determining whether other agents used in the castration‐resistant setting can be administered earlier in the hormone‐sensitive setting (<a href="./references#CD013245-bbs2-0052" title="SweeneyCJ , ChenYH , CarducciM , LiuG , JarrardDF , EisenbergerM , et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. New England Journal of Medicine2015;373(8):737-46.">Sweeney 2015</a>; <a href="./references#CD013245-bbs2-0030" title="JamesND , SydesMR , ClarkeNW , MasonMD , DearnaleyDP , SpearsMR , et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet2016;387(10024):1163-77.">James 2016</a>). </p> <p>Three systematic reviews have sought to critically appraise the entire body of trial evidence addressing this question. Rydzewska and colleagues omitted certain outcomes important to men with prostate cancer, such as quality of life, and did not use the GRADE approach to appraise the quality of evidence (<a href="./references#CD013245-bbs2-0042" title="RydzewskaLH , BurdettS , ValeCL , ClarkeNW , FizaziK , KheohT , et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. European Journal of Cancer2017;84:88-101.">Rydzewska 2017</a>). Two network meta‐analyses had similar shortcomings (<a href="./references#CD013245-bbs2-0056" title="ValeCL , FisherDJ , WhiteIR , CarpenterJR , BurdettS , ClarkeNW , et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology2018;29(5):1249-57.">Vale 2018</a>; <a href="./references#CD013245-bbs2-0057" title="WallisCJ , KlaassenZ , BhindiB , GoldbergH , ChandrasekarT , FarrellAM , et al. Comparison of abiraterone acetate and docetaxel with androgen deprivation therapy in high-risk and metastatic hormone-naive prostate cancer: a systematic review and network meta-analysis. European Urology2018;73(6):834-44.">Wallis 2018</a>). Therefore, this Cochrane Review will aim to critically evaluate the evidence in a prescribed manner, and focus on outcomes that are important to men with metastatic hormone‐sensitive prostate cancer, using the most methodologically rigorous approach. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013245-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013245-sec-0015"></div> <p>To assess the effects of early abiraterone acetate, in combination with androgen deprivation therapy, for newly diagnosed metastatic hormone‐sensitive prostate cancer. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013245-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013245-sec-0016"></div> <section id="CD013245-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013245-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised trials, regardless of their publication status or language of publication. We excluded cluster‐randomized, cross‐over and quasi‐randomized studies. </p> </section> <section id="CD013245-sec-0019"> <h4 class="title">Types of participants</h4> <p>We included studies that enrolled men with a confirmed histological diagnosis of adenocarcinoma of the prostate, and radiologic evidence of metastases, determined by cross‐sectional imaging (computer tomography [CT], magnetic resonance imaging [MRI], positron emission tomography [PET]), with or without bone scans. This included both men who had, and those who had not undergone local therapy. We only included men receiving immediate abiraterone acetate in combination with androgen deprivation therapy for their prostate cancer. Men who started abiraterone acetate within 120 days of beginning androgen deprivation therapy were considered to be receiving 'early' combination therapy. We included men who had previously received adjuvant or neoadjuvant androgen deprivation therapy if their metastases occurred at least 12 months after they stopped hormone therapy. Men receiving concurrent osteoprotective therapy (e.g. bisphosphonates) were eligible. </p> <p>We excluded men with advanced prostate cancer who received chemotherapy without known metastases, and those who received prior chemotherapy of any agent for their prostate cancer. </p> <p>If we identified studies in which only a subset of the men were relevant to this review, we included them if data were available separately for the relevant subset. </p> </section> <section id="CD013245-sec-0020"> <h4 class="title">Types of interventions</h4> <p>We investigated the following comparisons. Concomitant interventions had to be the same in the experimental and comparator groups to establish fair comparisons. </p> <section id="CD013245-sec-0021"> <h5 class="title">Experimental interventions</h5> <p> <ul id="CD013245-list-0001"> <li> <p>Abiraterone acetate and prednisone in combination with androgen deprivation therapy (using methods outlined under 'Comparator interventions' below). </p> </li> </ul> </p> </section> <section id="CD013245-sec-0022"> <h5 class="title">Comparator interventions</h5> <p> <ul id="CD013245-list-0002"> <li> <p>Androgen deprivation therapy alone (using luteinizing hormone‐releasing hormone agonist or antagonist; non‐steroidal antiandrogen monotherapy; combination of antiandrogen plus luteinizing hormone‐releasing hormone agonist [maximum androgen blockade], or bilateral orchiectomy). </p> </li> </ul> </p> </section> <section id="CD013245-sec-0023"> <h5 class="title">Comparisons</h5> <p> <ul id="CD013245-list-0003"> <li> <p>Abiraterone acetate and prednisone in combination with androgen deprivation therapy versus androgen deprivation therapy alone. </p> </li> </ul> </p> </section> </section> <section id="CD013245-sec-0024"> <h4 class="title">Types of outcome measures</h4> <p>We did not use the measurement of the outcomes assessed in this review as an eligibility criterion. </p> <section id="CD013245-sec-0025"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD013245-list-0004"> <li> <p>Time to death due to any cause</p> </li> <li> <p>Quality of life</p> </li> </ul> </p> </section> <section id="CD013245-sec-0026"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD013245-list-0005"> <li> <p>Grades III to V adverse events</p> </li> <li> <p>Time to death due to prostate cancer</p> </li> <li> <p>Time to disease progression</p> </li> <li> <p>Discontinued treatment due to adverse events</p> </li> </ul> </p> <section id="CD013245-sec-0027"> <h6 class="title">Method and timing of outcome measurement</h6> <p> <ul id="CD013245-list-0006"> <li> <p>Time to death due to any cause, was the time from randomization to death from any cause (time‐to‐event outcome). </p> </li> <li> <p>Overall quality of life at 12 months, or as reported; measured by validated instruments, such as the 12‐item Short Form (SF‐12), 36‐item Short Form (SF‐36), or Functional Assessment of Cancer Therapy ‐ Prostate Scales (FACT‐P; range 0 to 156; higher values indicate better quality of life) questionnaires (continuous outcome). </p> </li> <li> <p>Grades III to V adverse events at 12 months, or as reported, according to the Common Toxicity Criteria (CTCAE) v3.0; occurring at any time during treatment; such as sudden death, neutropenia, febrile neutropenia, fatigue, gastrointestinal disorders (including diarrhea, constipation, and vomiting), stomatitis, neuropathy, thromboembolism, thrombocytopenia, or renal impairment (dichotomous outcome). </p> </li> <li> <p>Time to death due to prostate cancer, was the time from randomization until death from prostate cancer (time‐to‐event outcome). </p> </li> <li> <p>Time to disease progression, was the time from randomization until clinical, biochemical, or radiographic progression (time‐to‐event outcome). Biochemical and radiographic progression were defined using the criteria specified by the Prostate Cancer Working Group 2 (<a href="./references#CD013245-bbs2-0047" title="ScherHI , HalabiS , TannockI , MorrisM , SternbergCN , CarducciMA , et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology2008;26(7):1148-59.">Scher 2008</a>). Clinical progression was defined as clinical deterioration due to cancer. </p> </li> <li> <p>Discontinued treatment due to adverse events, was the number of men who ceased treatment due to an adverse event caused by the treatment (dichotomous outcome). </p> </li> </ul> </p> <p>When we were unable to retrieve the information needed to analyze time‐to‐event outcomes, we attempted to assess the number of events per group, for dichotomized outcomes at one, three, and five years after starting abiraterone treatment (<a href="#CD013245-sec-0109">Differences between protocol and review</a>). </p> </section> <section id="CD013245-sec-0028"> <h6 class="title">Main outcomes for 'Summary of findings' table</h6> <p>We presented a 'Summary of findings' table reporting the following outcomes listed according to priority. </p> <p> <ol id="CD013245-list-0007"> <li> <p>Time to death due to any cause</p> </li> <li> <p>Quality of life</p> </li> <li> <p>Grades III to V adverse events</p> </li> <li> <p>Time to death due to prostate cancer</p> </li> <li> <p>Time to disease progression</p> </li> <li> <p>Discontinued treatment due to adverse events</p> </li> </ol> </p> </section> </section> </section> </section> <section id="CD013245-sec-0029"> <h3 class="title">Search methods for identification of studies</h3> <p>We conducted a comprehensive search with no restrictions on the language of publication, or publication status in October 2019. We re‐ran searches within six months of anticipated publication of the review to capture any recently published relevant records (15 May 2020). </p> <section id="CD013245-sec-0030"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from inception of each database.</p> <p> <ul id="CD013245-list-0008"> <li> <p>Cochrane Library 2020, issue 4 (searched 15 May 2020; <a href="./appendices#CD013245-sec-0096">Appendix 1</a>) </p> <ul id="CD013245-list-0009"> <li> <p><i>Cochrane Database of Systematic Reviews</i> (CDSR); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL);</p> </li> <li> <p>Database of Abstracts of Reviews of Effects (DARE);</p> </li> <li> <p>Health Technology Assessment Database (HTA);</p> </li> </ul> </li> <li> <p>MEDLINE via Ovid (1946 to 15 May 2020; <a href="./appendices#CD013245-sec-0097">Appendix 2</a>); </p> </li> <li> <p>Embase via Ovid (1947 to 15 May 2020; <a href="./appendices#CD013245-sec-0098">Appendix 3</a>); </p> </li> <li> <p>Scopus (1966 to 15 May 2020; <a href="./appendices#CD013245-sec-0099">Appendix 4</a>); </p> </li> <li> <p>Web of Science (1900 to 15 May 2020; <a href="./appendices#CD013245-sec-0100">Appendix 5</a>); </p> </li> <li> <p>LILACS (Latin American and the Caribbean Health Sciences Literature; 1982 to 15 May 2020; <a href="./appendices#CD013245-sec-0101">Appendix 6</a>). </p> </li> </ul> </p> <p>We also searched the following.</p> <p> <ul id="CD013245-list-0010"> <li> <p>ClinicalTrials.gov (<a href="https://www.clinicaltrials.gov/" target="_blank">www.clinicaltrials.gov</a>); </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (ICTRP) search portal (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch</a>); </p> </li> <li> <p>Grey literature repository from the current Grey Literature Report (<a href="http://www.greylit.org/" target="_blank">www.greylit.org</a>). </p> </li> </ul> </p> <p>We did not detect additional relevant key words during any of the electronic or other searches that necessitated modification of the search strategy. </p> </section> <section id="CD013245-sec-0031"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials, and identified reviews, meta‐analyses, and health technology assessment reports. We also contacted study authors of included trials to identify any further studies that we may have missed. We searched abstract proceedings of relevant meetings, such as the American Urological Association, European Association of Urology, and American Society of Clinical Oncology since the approval of abiraterone acetate (2011 to 2018) for unpublished studies. </p> </section> </section> <section id="CD013245-sec-0032"> <h3 class="title" id="CD013245-sec-0032">Data collection and analysis</h3> <section id="CD013245-sec-0033"> <h4 class="title">Selection of studies</h4> <p>We used reference management software to identify and remove potential duplicate records (<a href="./references#CD013245-bbs2-0015" title="EndNote. Version 7.5. Philadelphia (PA): Clarivate Analytics, 2016. Available at endnote.com.">EndNote 2016</a>). Two review authors (NS, MO) independently scanned the abstract, title, or both, of the remaining retrieved records, to determine which studies should be assessed further. Two review authors (NS, MO) independently investigated all potentially relevant records as full text, mapped records to studies, and classify studies as included studies, excluded studies, studies awaiting classification, or ongoing studies, in accordance with the criteria provided in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013245-bbs2-0025" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Higgins 2011a</a>). We resolved any discrepancies through consensus, or recourse to a third review author (FK) if needed. We documented reasons for excluding studies that may have reasonably been expected to be included in the review in a '<a href="./references#CD013245-sec-0113" title="">Characteristics of excluded studies</a>' table. We present a PRISMA flow diagram showing the process of study selection (<a href="./references#CD013245-bbs2-0033" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100. [DOI: 10.1371/journal.pmed.1000100]">Liberati 2009</a>). </p> </section> <section id="CD013245-sec-0034"> <h4 class="title">Data extraction and management</h4> <p>We developed a dedicated data abstraction form that we pilot tested ahead of time.</p> <p>For studies that fulfilled inclusion criteria, two review authors (NS, IW) independently abstracted the following information, details of which are in the '<a href="./references#CD013245-sec-0112" title="">Characteristics of included studies</a>' table. </p> <p> <ul id="CD013245-list-0011"> <li> <p>Study design;</p> </li> <li> <p>Study dates (if dates are not available then this will be reported as such);</p> </li> <li> <p>Study settings and country;</p> </li> <li> <p>Participant inclusion and exclusion criteria (e.g. age, disease stage, comorbidities, pretreatment); </p> </li> <li> <p>Participant details, baseline demographics (e.g. age, disease stage);</p> </li> <li> <p>The number of participants by study arm;</p> </li> <li> <p>Details of relevant experimental and comparator interventions, such as dose, route, frequency, and duration; </p> </li> <li> <p>Definitions of relevant outcomes, method and timing of outcome measurement, as well as any relevant subgroups; </p> </li> <li> <p>Study funding sources;</p> </li> <li> <p>Declarations of interest by primary investigators.</p> </li> </ul> </p> <p>We extracted outcome data relevant to this Cochrane Review as needed to calculate summary statistics and measures of variance. For dichotomous outcomes, we attempted to obtain numbers of events and totals to populate a 2×2 table, as well as summary statistics with corresponding measures of variance. For continuous outcomes, we attempted to obtain means and standard deviations, or data necessary to calculate this information. For time‐to‐event outcomes, we attempted to obtain hazard ratios (HRs) with corresponding measures of variance, or data necessary to calculate this information. </p> <p>We resolved any disagreements by discussion; if required, we consulted with a third review author (FK). </p> <p>In future, if we identify any, we will provide information, including trial identifier, on potentially relevant ongoing studies in the 'Characteristics of ongoing studies' table. </p> <p>We attempted to contact authors of included studies to obtain key missing data as needed. </p> <section id="CD013245-sec-0035"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>We maximized yield of information by mapping all publications (duplicate publications, companion documents, or multiple reports of the study) to a unique study ID, and collating all available data. We used the most complete dataset, aggregated across all known publications. If in doubt, we gave priority to the publication reporting the longest follow‐up associated with our primary or secondary outcomes. </p> </section> </section> <section id="CD013245-sec-0036"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (NS, MO) independently assessed the risk of bias of each included study. We resolved disagreements by consensus, or by consulting with a third review author (FK). </p> <p>We assessed risk of bias using Cochrane's 'Risk of bias' assessment tool (<a href="./references#CD013245-bbs2-0026" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Higgins 2011b</a>). We assessed the following domains. </p> <p> <ul id="CD013245-list-0012"> <li> <p>Random sequence generation (selection bias);</p> </li> <li> <p>Allocation concealment (selection bias);</p> </li> <li> <p>Blinding of participants and personnel (performance bias);</p> </li> <li> <p>Blinding of outcome assessment (detection bias);</p> </li> <li> <p>Incomplete outcome data (attrition bias);</p> </li> <li> <p>Selective reporting (reporting bias);</p> </li> <li> <p>Other sources of bias.</p> </li> </ul> </p> <p>We judged 'Risk of bias' domains as low risk, high risk, or unclear risk, and evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013245-bbs2-0026" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Higgins 2011b</a>). We presented a 'Risk of bias' summary figure to illustrate these findings. </p> <p>For selection bias (random sequence generation and allocation concealment), we evaluated risk of bias at a trial level. </p> <p>For performance bias (blinding of participants and personnel), we considered that all outcomes were similarly susceptible to performance bias. </p> <p>For detection bias (blinding of outcome assessment), we grouped outcomes as susceptible to detection bias (subjective), or not susceptible to detection bias (objective). </p> <p>We defined the following as subjective outcomes.</p> <p> <ul id="CD013245-list-0013"> <li> <p>Serious adverse events;</p> </li> <li> <p>Time to death due to prostate cancer;</p> </li> <li> <p>Time to disease progression;</p> </li> <li> <p>Discontinued treatment due to adverse events;</p> </li> <li> <p>Quality of life.</p> </li> </ul> </p> <p>We defined the following as an objective outcome.</p> <p> <ul id="CD013245-list-0014"> <li> <p>Time to death due to any cause.</p> </li> </ul> </p> <p>We assessed attrition bias (incomplete outcome data) on an outcome‐specific basis, and presented the judgement for each outcome separately in the 'Risk of bias' tables. </p> <p>For reporting bias (selective reporting), we evaluated risk of bias at a trial level.</p> <p>We further summarized the risk of bias across domains for each outcome in each included study, and across studies and domains for each outcome, in accordance with the approach for summary assessments of the risk of bias presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013245-bbs2-0026" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Higgins 2011b</a>). </p> </section> <section id="CD013245-sec-0037"> <h4 class="title">Measures of treatment effect</h4> <p>We expressed dichotomous data as risk ratios (RRs) with 95% confidence intervals (CIs). We expressed continuous data as mean differences (MDs) with 95% CIs, unless different studies used different measures to assess the same outcome, in which case we expressed data as standardized mean differences (SMD) with 95% CIs. We expressed time‐to‐event data as hazard ratios (HRs) with 95% CIs. </p> </section> <section id="CD013245-sec-0038"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of analysis was the individual man.</p> </section> <section id="CD013245-sec-0039"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to obtain missing data from study authors, and conducted intention‐to‐treat (ITT) analyses if data were available; otherwise, we conducted available case analyses. We investigated attrition rates, e.g. dropouts, losses to follow‐up, and withdrawals, and critically appraised issues of missing data. We did not impute missing data. </p> </section> <section id="CD013245-sec-0040"> <h4 class="title">Assessment of heterogeneity</h4> <p>We identified heterogeneity (inconsistency), by visually inspecting the forest plots to assess the amount of overlap of CIs, and calculating the I² statistic, which quantifies inconsistency across studies, to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD013245-bbs2-0023" title="HigginsJP , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21(11):1539-58. [DOI: 10.1002/sim.1186]">Higgins 2002</a>; <a href="./references#CD013245-bbs2-0024" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed.)2003;327(7414):557-60. [DOI: 10.1136/bmj.327.7414.557]">Higgins 2003</a>). We interpreted the I² statistic as follows (<a href="./references#CD013245-bbs2-0014" title="DeeksJJ , HigginsJP , AltmanDG , editor(s). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Deeks 2011</a>): </p> <p> <ul id="CD013245-list-0015"> <li> <p>0% to 40%: may not be important</p> </li> <li> <p>30% to 60%: may indicate moderate heterogeneity</p> </li> <li> <p>50% to 90%: may indicate substantial heterogeneity</p> </li> <li> <p>75% to 100%: considerable heterogeneity</p> </li> </ul> </p> <p>If we found heterogeneity, we attempted to determine possible reasons for it by examining individual study and subgroup characteristics. </p> </section> <section id="CD013245-sec-0041"> <h4 class="title">Assessment of reporting biases</h4> <p>We attempted to obtain study protocols to assess for selective outcome reporting. We did not use funnel plots to assess for reporting bias because we only included two trials. </p> </section> <section id="CD013245-sec-0042"> <h4 class="title">Data synthesis</h4> <p>We summarized data using a random‐effects model. We interpreted random‐effects meta‐analyses with due consideration of the whole distribution of effects. In addition, we conducted statistical analyses according to the statistical guidelines outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD013245-bbs2-0025" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Higgins 2011a</a>). For dichotomous outcomes, we used the Mantel‐Haenszel method; for continuous outcomes, we used the inverse variance method; and for time‐to‐event outcomes, we used the generic inverse variance method. We used <a href="./references#CD013245-bbs2-0039" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a> software to perform analyses. </p> </section> <section id="CD013245-sec-0043"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to be potential effect modifiers, and carried out subgroup analyses to investigate interactions. </p> <p> <ul id="CD013245-list-0016"> <li> <p>Volume of metastases: high volume, defined according to expert consensus as visceral, four or more bone metastases including one beyond the pelvis and vertebral column, or both, versus low volume (<a href="./references#CD013245-bbs2-0017" title="GillessenS , OmlinA , AttardG , deBonoJS , EfstathiouE , FizaziK , et al. Management of patients with advance prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology2015;26(8):1589-604.">Gillessen 2015</a>) </p> </li> <li> <p>Previous local treatment: men who had undergone radical surgery, or radiation therapy, or both, and then developed metastases were separated from those who had not undergone any previous treatment, and instead presented with metastatic disease. </p> </li> </ul> </p> <p>We tested for subgroup differences in <a href="./references#CD013245-bbs2-0039" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a> to compare subgroup analyses. </p> </section> <section id="CD013245-sec-0044"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses on the primary outcomes in order to explore the influence of the following factors (when applicable) on effect sizes. </p> <p> <ul id="CD013245-list-0017"> <li> <p>Restricting the analysis by taking into account risk of bias, by excluding studies at high risk or unclear risk. Studies with more than two bias domains assessed as unclear risk, were classified as being at high risk from bias, overall. </p> </li> </ul> </p> </section> <section id="CD013245-sec-0045"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We presented the overall quality of the evidence for each outcome according to the GRADE approach, which takes into account five criteria, related to internal validity (risk of bias, inconsistency, imprecision, publication bias), and external validity (directness of results; [<a href="./references#CD013245-bbs2-0019" title='GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , SchünemannHJ , et al. What is "quality of evidence" and why is it important to clinicians?BMJ (Clinical Research Ed.)2008;336(7651):995-8. [DOI: 10.1136/bmj.39490.551019.BE]'>Guyatt 2008</a>])<i>.</i> For each comparison, two review authors (NS and MO) independently rated the quality of evidence for each outcome as high, moderate, low, or very low, using <a href="./references#CD013245-bbs2-0018" title="GRADEpro GDT. Version accessed prior to 04 July 2020. Hamilton (ON): McMaster University (developed by Evidence Prime), N/A. Available at gradepro.org.">GRADEpro GDT</a>. We resolved any discrepancies by consensus, or, if needed, by arbitration by a third review author (FK). For each comparison, we presented a summary of the evidence for the main outcomes in a 'Summary of findings' table, which provides key information about the best estimate of the magnitude of the effect in relative terms and absolute differences, for each relevant comparison of alternative management strategies; numbers of participants and studies addressing each important outcome; and the rating of the overall confidence in the estimate of effect for each outcome (<a href="./references#CD013245-bbs2-0020" title="GuyattG , OxmanAD , AklEA , KunzR , VistG , BrozekJ , et al. GRADE guidelines: 1. Introduction – GRADE evidence profiles and summary of findings tables. Journal of Clinical Epidemiology2011;64(4):383-94. [DOI: 10.1016/j.jclinepi.2010.04.026]">Guyatt 2011</a>; <a href="./references#CD013245-bbs2-0049" title="SchünemannHJ , OxmanAD , HigginsJP , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JP, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/cochrane-handbook.">Schünemann 2011</a>). If meta‐analysis was not possible, we presented results in a narrative 'Summary of findings' table. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013245-sec-0046" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013245-sec-0046"></div> <section id="CD013245-sec-0047"> <h3 class="title">Description of studies</h3> <p>We included two randomized controlled trials (RCT), details of which are presented in the '<a href="./references#CD013245-sec-0112" title="">Characteristics of included studies</a>' table, <a href="#CD013245-tbl-0002">Table 1</a>, and <a href="#CD013245-tbl-0003">Table 2</a>. </p> <div class="table" id="CD013245-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparators (route, frequency, total dose/day)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LATITUDE (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone acetate (1000 mg daily, given once daily as four 250 mg tablets) and prednisone (5 mg daily) in addition to ADT, given through either bilateral orchidectomy or luteinizing hormone releasing hormone (LHRH) agonists </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone, given through either bilateral orchidectomy or LHRH agonists</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>STAMPEDE (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone (1000 mg) with prednisolone (5 mg), given once daily in addition to ADT, given through LHRH agonists or antagonists, bilateral orchidectomy, combined androgen blockade </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone, given through LHRH agonists or antagonists, bilateral orchidectomy, combined androgen blockade </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>ADT: androgen deprivation therapy; C: comparator; I: intervention</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013245-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and comparator</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of follow‐up</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median age</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prior local therapy (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gleason 8 to 10 (%)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone acetate (1000 mg daily, given once daily as four 250 mg tablets) and prednisone (5 mg daily) in addition to ADT<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>597</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 years (range 38 to 89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 years (range 33 to 92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone (1000 mg) with prednisolone (5 mg), given once daily in addition to ADT<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Until<br/>death of<br/>all randomised<br/>men </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 years (range 42 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 years (range 39 to 84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>NR: not reported<br/>ADT: androgen deprivation therapy<br/>C: comparator; I: intervention; SD: standard deviation </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>The following therapies were classified as ADT: luteinizing hormone releasing hormone agonists or antagonists, bilateral orchidectomy, combined androgen blockade </p> </div> </div> <section id="CD013245-sec-0048"> <h4 class="title">Results of the search</h4> <p>We identified 4611 records through database searching up to 15 May 2020. After removing duplicates, we screened the titles and abstracts of 3959 records, 3935 of which we eliminated as not eligible. We reviewed 27 full‐text articles, and excluded three trials (four records) that did not meet the inclusion criteria. We included a total of two studies (23 records) in this review. We did not identify any trials that were either ongoing, or completed but not yet published. The flow of literature through the assessment process is shown in the PRISMA flowchart (<a href="#CD013245-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD013245-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD013245-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD013245-sec-0049"> <h4 class="title">Included studies</h4> <section id="CD013245-sec-0050"> <h5 class="title">Sources of data</h5> <p>Both included trials were identified through the literature search. There were multiple abstracts and conference proceedings for each of the included trials. </p> </section> <section id="CD013245-sec-0051"> <h5 class="title">Study design and settings</h5> <p>The included studies were both randomized trials; <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> (LATITUDE trial) was described as a double‐blind, placebo‐controlled study, whereas <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> (STAMPEDE trial) was an open‐label study. </p> </section> <section id="CD013245-sec-0052"> <h5 class="title">Participants</h5> <p>This review included a total of 2201 men with metastatic, hormone‐sensitive prostate cancer, 1097 of whom received abiraterone acetate and prednisone in addition to androgen deprivation therapy. One trial also enrolled 915 men with non‐metastatic disease, who were not included in this review (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> <p>The STAMPEDE trial (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>) did not report baseline characteristics separately for the subgroup of men with metastatic, hormone‐sensitive disease, and therefore, the following data are from the LATITUDE trial (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>) only. The median age and range of the men in the intervention group was 68 years (38 to 89) and 67 years (33 to 92) in the control group. The prostate cancer in nearly all of the men (97.6%) in <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> had a Gleason score of at least 8 (grade IV). A similar proportion of the men also had at least three bony metastases at the time of screening (97.7%). The majority of men in <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> had undergone previous treatment for their prostate cancer (93.4%). In contrast, in the metastatic subgroup in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>, nearly all of the men were newly diagnosed with their metastases, and had no previous prostate cancer treatment (93.9%). </p> <p>The inclusion criteria included men over the age of 18 years, who had histologically or cytologically proven adenocarcinoma of the prostate, and metastatic disease proven by computer tomography (CT) or magnetic resonance imaging (MRI). Histological confirmation was not required in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> if the men had multiple sclerotic bone metastases with a prostate‐specific antigen (PSA) ≥100 ng/mL. Men in <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> were required to have two of the following three high‐risk prognostic factors: Gleason score ≥ 8, at least three lesions on bone scan, or the presence of visceral metastases. </p> <p>Men who had undergone previous curative treatment for their metastatic prostate cancer were excluded. However, <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> permitted the men to receive up to three months of pharmacological or surgical castration therapy. <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> permitted adjuvant or neoadjuvant hormone treatment, as long as therapy had been completed at least 12 months prior to randomization, and had been no longer than 12 months in duration. <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> excluded men with small cell carcinoma of the prostate, brain metastases, or other active malignancies. </p> </section> <section id="CD013245-sec-0053"> <h5 class="title">Interventions and comparators</h5> <p>The two included trials administered abiraterone acetate 1000 mg once daily with low‐dose prednisone (5 mg) to the men in the active intervention arm until PSA, radiological, or clinical progression of the disease, or until another treatment was started. All of the men were given androgen deprivation therapy (ADT) through either surgical or pharmacological means, at the discretion of the investigator. </p> </section> <section id="CD013245-sec-0054"> <h5 class="title">Outcomes</h5> <p>Time to death due to any cause was reported in both trials, and we analyzed the data using an intention‐to‐treat approach. We analyzed quality of life using the Functional Assessment of Cancer Therapy–prostate (FACT‐P) score from <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>, through additional data provided by the study authors. <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> did not report this outcome. </p> <p>Data for time to death from prostate cancer, and time to disease progression were available in both trials. Only <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> provided the required information for grades III to V adverse events, and discontinued treatment due to adverse events. There were insufficient data in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>, because although these outcomes were assessed, the published manuscript reported both non‐metastatic and metastatic participants together, and did not stratify the outcome by these subgroups. </p> <p>We contacted authors of both included studies to obtain additional data. but only received additional data from <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>. </p> </section> <section id="CD013245-sec-0055"> <h5 class="title">Funding</h5> <p>Both trials received funding from Janssen, which developed abiraterone acetate. <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> also received funding from other industry and government sources. Conflicts of interests with pharmaceutical companies were reported in all studies. </p> </section> </section> <section id="CD013245-sec-0056"> <h4 class="title">Excluded studies</h4> <p>We excluded three studies, which are outlined in the '<a href="./references#CD013245-sec-0113" title="">Characteristics of excluded studies</a>' table. Two studies were excluded because the comparator was docetaxel plus ADT rather than ADT alone (<a href="./references#CD013245-bbs2-0005" title="SydesMR , MasonMD , SpearsMR , ClarkeNW , DearnaleyD , RitchieAWS , et al. Adding abiraterone acetate plus prednisolone (AAP) or docetaxel for patients (pts) with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Directly randomised data from STAMPEDE (NCT00268476). Annals of Oncology2017;28(Suppl 5):v619. SydesMR , SpearsMR , MasonMD , ClarkeNW , DearnleyDP , deBonoJS . Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Annals of Oncology2018;29(5):1235-48. ">Sydes 2017</a>; <a href="./references#CD013245-bbs2-0004" title="FeyerabendS , SaadF , LiT , ItoT , DielsJ , SandenSV . Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naive prostate cancer (mCNPC). Journal of Clinical Oncology2018;36(Suppl 6):200. ">Feyerabend 2018</a>); the third was the wrong study design. </p> </section> </section> <section id="CD013245-sec-0057"> <h3 class="title">Risk of bias in included studies</h3> <p>Detailed results of the ’Risk of Bias’ assessment are provided in <a href="#CD013245-fig-0002">Figure 2</a> and <a href="#CD013245-fig-0003">Figure 3</a>, and the judgements for individual domains are provided in the '<a href="./references#CD013245-sec-0112" title="">Characteristics of included studies</a>' table. </p> <div class="figure" id="CD013245-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013245-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> </div> <div class="figure" id="CD013245-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD013245-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD013245-sec-0058"> <h4 class="title">Allocation</h4> <section id="CD013245-sec-0059"> <h5 class="title">Random sequence generation</h5> <p>We rated both trials at low risk of bias because either computer algorithms were used (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>), or the sequence was created centrally, by an independent, uninvolved, third‐party (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>). </p> </section> <section id="CD013245-sec-0060"> <h5 class="title">Allocation concealment</h5> <p>We rated both trials at low risk of bias because allocation was performed centrally.</p> </section> </section> <section id="CD013245-sec-0061"> <h4 class="title">Blinding</h4> <section id="CD013245-sec-0062"> <h5 class="title">Blinding of participants and personnel</h5> <p>We rated <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> at low risk of performance bias, because we judged that both participants and personnel were appropriately blinded, whereas <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> was an open‐label trial, and at high risk of performance bias. </p> </section> <section id="CD013245-sec-0063"> <h5 class="title">Blinding of outcome assessment</h5> <p> <ul id="CD013245-list-0018"> <li> <p>Time to death due to any cause: this is an objective outcome that is unlikely to be affected by blinding, and therefore, we rated both studies at low risk of detection bias. </p> </li> <li> <p>Quality of life: this was measured by self‐assessment questionnaires that were completed by blinded participants in <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>, and therefore, we rated it at low risk of detection bias; participants were not blinded in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>, and thus, we rated it at high risk of performance bias. </p> </li> <li> <p>Grades III to V adverse events: blinded investigators determined the severity of adverse events in <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>, so we rated this at low risk of detection bias. Unblinded investigators rated the severity of adverse events in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>, so we rated it at high risk of performance bias. </p> </li> <li> <p>Time to death due to prostate cancer: we rated <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> at low risk of bias because the cause of death was determined by a blinded reviewer. It was not clear who was responsible for determining the cause of death in <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>, or whether they were appropriately blinded, therefore, we rated this as unclear risk of bias. </p> </li> <li> <p>Time to disease progression: we rated <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> at low risk of bias, because Individuals who determined progression (using radiology, PSA, or both) were blinded. There was no information in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> regarding the blinded status of the individuals who assessed progression, and thus, we rated this as unclear risk of bias. </p> </li> <li> <p>Discontinued treatment due to adverse events: we rated <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> at low risk of bias, because although not clearly specified, the reasons for discontinuing treatment were likely to be reported by investigators who were blinded to treatment allocation. There was no information in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> regarding blinding of the individuals responsible for determining the reasons for discontinued treatment, and therefore, we rated it as unclear risk of bias. </p> </li> </ul> </p> </section> </section> <section id="CD013245-sec-0064"> <h4 class="title">Incomplete outcome data</h4> <p>We grouped outcomes into groups of similar susceptibility to attrition bias: oncological outcomes (time to death due to any cause, time to death due to prostate cancer, time to progression), quality of life, and toxicity outcomes (grades III to V adverse events and discontinuing due to adverse events). </p> <p> <ul id="CD013245-list-0019"> <li> <p>Oncological outcomes: we rated both studies at low risk of bias, because the men were analyzed in the groups to which they were randomized, in an intention‐to‐treat manner, and the rates of loss to follow‐up were low. </p> </li> <li> <p>Quality of life: we rated <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> at high risk of attrition bias, because 70% of the men completed the FACT‐P score at 12 months. Quality of life was not reported in <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>. </p> </li> <li> <p>Toxicity outcomes: we rated both studies at low risk bias, because the men were analyzed in the group to which they were randomized, in an intention‐to‐treat manner, and the rates of loss to follow‐up were low. </p> </li> </ul> </p> </section> <section id="CD013245-sec-0065"> <h4 class="title">Selective reporting</h4> <p>We rated <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> at low risk of reporting bias, because they reported all outcomes pre‐specified in the protocol. We rated <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> at high risk of reporting bias, because quality of life was stated as a secondary outcome in the protocol, but was not reported. </p> </section> <section id="CD013245-sec-0066"> <h4 class="title">Other potential sources of bias</h4> <p>We did not find any other sources of bias in the two included studies, and therefore, we other sources of bias at low risk. </p> </section> </section> <section id="CD013245-sec-0067"> <h3 class="title" id="CD013245-sec-0067">Effects of interventions</h3> <p>See: <a href="./full#CD013245-tbl-0001"><b>Summary of findings 1</b> Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer</a> </p> <section id="CD013245-sec-0068"> <h4 class="title">1. Abiraterone acetate and prednisone in combination with androgen deprivation therapy versus androgen deprivation therapy only </h4> <section id="CD013245-sec-0069"> <h5 class="title">1.1 Time to death due to any cause</h5> <p>Two trials measured this outcome (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>; <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> <p>Abiraterone acetate in addition to androgen deprivation therapy (ADT) reduced the probability of dying from any cause more than ADT alone (hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.56 to 0.73; two RCTs, 2201 men; <a href="./references#CD013245-fig-0005" title="">Analysis 1.1</a>; <a href="#CD013245-fig-0004">Figure 4</a>; high‐certainty evidence). Compared to the five‐year survival for stage IV prostate cancer in the Surveillance, Epidemiology, and End Results (SEER) registry in the pre‐docetaxel era (2007 to 2013; <a href="./references#CD013245-bbs2-0038" title="RawlaP . Epidemiology of Prostate Cancer. World J Oncol2019;10(2):63-89.">Rawla 2019</a>), the addition of abiraterone acetate resulted in 163 fewer deaths (95% CI ‐210 to ‐115) from all causes per 1000 men with hormone‐sensitive metastatic prostate cancer. </p> <div class="figure" id="CD013245-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Abiraterone + ADT vs ADT alone, outcome: 1.1 Time to death due to any cause." data-id="CD013245-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Abiraterone + ADT vs ADT alone, outcome: 1.1 Time to death due to any cause. </p> </div> </div> </div> </section> <section id="CD013245-sec-0070"> <h5 class="title">1.2 Quality of life</h5> <p>One trial measured quality of life with the FACT‐P questionnaire (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>). </p> <p>Abiraterone acetate in addition to ADT probably results in a small, likely not clinically meaningful improvement in quality of life at 12 months compared to ADT alone (mean difference [MD] 2.90 points, 95% CI 0.11 to 5.60; one RCT, 838 men; <a href="./references#CD013245-fig-0006" title="">Analysis 1.2</a>; moderate‐certainty evidence) assuming a minimally clinically important difference of 6 ‐ 10 (<a href="./references#CD013245-bbs2-0009" title="CellaD , NicholMB , EtonD , NelsonJB , MulaniP . Estimating clinically meaningful changes for the functional assessment of cancer therapy – prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value in Health2009;12(1):124-9.">Cella 2009</a>). We downgraded the certainty of the evidence due to concerns regarding possible attrition bias. </p> </section> <section id="CD013245-sec-0071"> <h5 class="title">1.3 Grades III to V adverse events</h5> <p>One trial measured grades III to V severe adverse events (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>). </p> <p>Abiraterone acetate in addition to ADT increases the risk of grades III to V adverse events compared to ADT alone (risk ratio [RR] 1.34, 95% CI 1.22 to 1.47; one RCT, 1199 men; <a href="./references#CD013245-fig-0007" title="">Analysis 1.3</a>; high‐certainty evidence). This corresponds to 162 more (95% CI 105 to 224) grades III to IV adverse events per 1000 men treated with abiraterone acetate and ADT compared to ADT alone, at a median follow‐up of 30 months. </p> </section> <section id="CD013245-sec-0072"> <h5 class="title">1.4 Time to death due to prostate cancer</h5> <p>Two trials measured this outcome (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>; <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> <p>Abiraterone acetate in addition to ADT probably reduces the probability of prostate cancer‐specific death compared to ADT alone (HR 0.58, 95% CI 0.50 to 0.68; two RCTs, 2201 men; <a href="./references#CD013245-fig-0008" title="">Analysis 1.4</a>; moderate‐certainty evidence). Compared to the event rate in the control arm of the LATITUDE trial at a median follow‐up of 30.4 months, the addition of abiraterone acetate resulted in 120 fewer (95% CI ‐145 to ‐90) deaths from prostate cancer per 1000 men with hormone‐sensitive metastatic prostate cancer (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>). We downgraded the level of the certainty due to concerns regarding possible performance bias. </p> </section> <section id="CD013245-sec-0073"> <h5 class="title">1.5. Time to disease progression</h5> <p>Two trials measured this outcome (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>, <a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> <p>Abiraterone acetate in addition to ADT probably reduces the probability of progression of disease compared to ADT alone (HR 0.35, 95% CI 0.26 to 0.49; two RCTs, 2201 men; <a href="./references#CD013245-fig-0009" title="">Analysis 1.5</a>; moderate‐certainty evidence). Compared to the three‐year event rate in the control arm of the STAMPEDE trial, the addition of abiraterone acetate resulted in 369 fewer (95% CI ‐456 to ‐256) incidents of disease progression per 1000 men with hormone‐sensitive metastatic prostate cancer (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). We downgraded the certainty of the evidence due to concerns regarding possible detection bias. </p> </section> <section id="CD013245-sec-0074"> <h5 class="title">1.6 Discontinued treatment due to adverse events</h5> <p>One trial measured this event (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>). </p> <p>Abiraterone acetate in addition to ADT probably increases the risk of discontinuing treatment due to adverse events compared to ADT alone (RR 1.50, 95% CI 1.17 to 1.92; one RCT, 1199 men; <a href="./references#CD013245-fig-0010" title="">Analysis 1.6</a>; moderate‐certainty evidence). This corresponds to 51 more men (95% CI 17 to 93) discontinuing treatment because of adverse events per 1000 men treated with abiraterone acetate and ADT compared to ADT alone, at a median follow‐up of 30 months. We downgraded the certainty of the evidence due to concerns regarding possible detection bias and imprecision. </p> </section> </section> <section id="CD013245-sec-0075"> <h4 class="title">2. Subgroup analysis: volume of metastases</h4> <section id="CD013245-sec-0076"> <h5 class="title">2.1 Time to death due to any cause</h5> <p>The probability of dying from any cause for men with low volume of metastases was HR 0.68 (95% CI 0.50 to 0.91); for men with high volume of metastases it was HR 0.61 (95% CI 0.53 to 0.71; <a href="./references#CD013245-fig-0011" title="">Analysis 2.1</a>). The test for interaction was not significant (P = 0.56; I² = 0%). </p> </section> <section id="CD013245-sec-0077"> <h5 class="title">2.2 Quality of life</h5> <p>The mean difference in FACT‐P scores for the men with low volume of metastases who received abiraterone acetate was ‐2.03 (95%CI ‐10.98 to 6.92); for men with high volume of metastases, the mean difference was 3.68 (95%CI 0.73 to 6.63; <a href="./references#CD013245-fig-0012" title="">Analysis 2.2</a>). The test for interaction was not significant (P = 0.23; I² = 29%). </p> </section> <section id="CD013245-sec-0078"> <h5 class="title">2.3 Grades III to V adverse events</h5> <p>We were unable to obtain the required data to conduct a subgroup analysis for this outcome. </p> </section> <section id="CD013245-sec-0079"> <h5 class="title">2.4 Time to death due to prostate cancer</h5> <p>The probability of dying from prostate cancer for men with low volume disease was HR 0.67 (95%C CI 0.44 to 1.01); for men with high volume disease it was HR 0.57 (95% CI 0.49 to 0.67; <a href="./references#CD013245-fig-0013" title="">Analysis 2.3</a>). The test for interaction was not significant (P = 0.50; I² = 0%). </p> </section> <section id="CD013245-sec-0080"> <h5 class="title">2.5 Time to progression</h5> <p>The probability of progression of disease for men with low volume of metastases was HR 0.46 (95% CI 0.33 to 0.63); for men with high volume of metastases, the HR was 0.46 (95% CI 0.31 to 0.69; <a href="./references#CD013245-fig-0014" title="">Analysis 2.4</a>). The test for interaction was not significant (P = 0.97; I² = 0%). </p> </section> <section id="CD013245-sec-0081"> <h5 class="title">2.6 Treatment discontinued due to adverse events</h5> <p>We were unable to obtain the required data to conduct a subgroup analysis for this outcome. </p> </section> </section> <section id="CD013245-sec-0082"> <h4 class="title">3. Subgroup analysis: previous local treatment</h4> <p>We were unable to obtain the required data to conduct a subgroup analysis for this outcome. </p> </section> <section id="CD013245-sec-0083"> <h4 class="title">4. Sensitivity analysis</h4> <p>For the primary outcome of time to death due to any cause, we rated both trials at overall low risk of bias, therefore, the results of the sensitivity analysis are the same as <a href="./references#CD013245-fig-0005" title="">Analysis 1.1</a>. </p> <p>For grades III to V adverse events, we only rated <a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> at overall low risk of bias, therefore, the results of the sensitivity analysis are the same as <a href="./references#CD013245-fig-0007" title="">Analysis 1.3</a>. </p> <p>We were unable to conduct a sensitivity analysis for quality of life.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013245-sec-0084" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013245-sec-0084"></div> <section id="CD013245-sec-0085"> <h3 class="title" id="CD013245-sec-0085">Summary of main results</h3> <p>We included two randomized trials with 2201 men (<a href="#CD013245-tbl-0002">Table 1</a>; <a href="#CD013245-tbl-0003">Table 2</a>). Compared to androgen deprivation therapy (ADT) alone, the addition of abiraterone acetate to ADT for metastatic hormone‐sensitive prostate cancer probably improves overall and progression‐free survival. The addition of abiraterone acetate to ADT appears to result in a large reduction in the risk of progression. It also probably reduces the probability of prostate cancer‐specific death, and leads to a small, and not clinically meaningful improvement in quality of life. However, the addition of abiraterone acetate to ADT probably increases the risk of grades III to V adverse events, and discontinued treatment from adverse events. The benefit of adding abiraterone acetate to ADT is seen in both low‐ and high‐volume disease. </p> </section> <section id="CD013245-sec-0086"> <h3 class="title" id="CD013245-sec-0086">Overall completeness and applicability of evidence</h3> <p>The majority of included men were newly diagnosed with metastatic prostate cancer, and thus, we are uncertain whether the treatment effect would be the same for those with prior local treatment, although there is currently no evidence to suggest otherwise. We had concerns regarding attrition bias for the quality of life outcome, because only 70% of the men in the LATITUDE study completed the questionnaire at 12 months; therefore, this may not reliably reflect the true treatment effect for this population. </p> <p>There were insufficient data to conduct all of the intended subgroup analyses, so we are uncertain whether the volume of disease or prior local treatment impacts the effectiveness of abiraterone acetate; the limited data available for some of the outcomes did not show any difference. Post hoc analysis in the STAMPEDE trial did show that overall survival was improved with the addition of abiraterone acetate in men with de novo metastatic disease, regardless of disease volume (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> <p>Both of the included studies were funded by industry, and study authors had extensive relationships with industry. This should be considered when interpreting and applying the results. </p> </section> <section id="CD013245-sec-0087"> <h3 class="title" id="CD013245-sec-0087">Quality of the evidence</h3> <p>Overall, we rated the certainty of evidence as moderate or high, reflecting the methodological robustness of the trials included in this review, especially the LATITUDE study, which was a double‐blind, randomized trial, in which both participants and personnel were appropriately randomized, allocation was concealed, and they were blind to the treatment group (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>). On the other hand, the STAMPEDE trial was an open‐label study, and therefore, when data from this trial were included, we downgraded the evidence by one level due to study limitations, for risk of performance and detection biases (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> </section> <section id="CD013245-sec-0088"> <h3 class="title" id="CD013245-sec-0088">Potential biases in the review process</h3> <p>Despite a comprehensive search strategy, without any publication or language restrictions, there is a possibility that we may have missed studies published in a language other than English, in non‐indexed journals, or not published at all. The number of studies included in this review was insufficient to generate funnel plots; therefore, we may have underestimated the risk of publication bias. </p> </section> <section id="CD013245-sec-0089"> <h3 class="title" id="CD013245-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>The findings of this review are largely consistent with those published previously. <a href="./references#CD013245-bbs2-0042" title="RydzewskaLH , BurdettS , ValeCL , ClarkeNW , FizaziK , KheohT , et al. Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. European Journal of Cancer2017;84:88-101.">Rydzewska 2017</a>, <a href="./references#CD013245-bbs2-0056" title="ValeCL , FisherDJ , WhiteIR , CarpenterJR , BurdettS , ClarkeNW , et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology2018;29(5):1249-57.">Vale 2018</a> and <a href="./references#CD013245-bbs2-0045" title="SathianathenNJ , KoschelS , ThangasamyIA , TehJ , AlghazoO , ButcherG , et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. European Urology2019;77(3):365-72. [DOI: 10.1016/j.eururo.2019.09.004] [PMID: 31679970]">Sathianathen 2019</a> all reported that abiraterone acetate with prednisolone plus ADT improved overall survival compared to ADT alone. It should be noted that <a href="./references#CD013245-bbs2-0056" title="ValeCL , FisherDJ , WhiteIR , CarpenterJR , BurdettS , ClarkeNW , et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Annals of Oncology2018;29(5):1249-57.">Vale 2018</a> and <a href="./references#CD013245-bbs2-0045" title="SathianathenNJ , KoschelS , ThangasamyIA , TehJ , AlghazoO , ButcherG , et al. Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis. European Urology2019;77(3):365-72. [DOI: 10.1016/j.eururo.2019.09.004] [PMID: 31679970]">Sathianathen 2019</a> were network meta‐analyses that indirectly compared abiraterone acetate with prednisolone plus ADT to docetaxel plus ADT, and reported that it was most probable that abiraterone was the superior agent in this setting. The findings in this review are the most up to date, as it includes data that were not available previously, such as the subgroup analysis by the CHAARTED volume of disease criteria (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013245-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD013245-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study" data-id="CD013245-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies." data-id="CD013245-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Abiraterone + ADT vs ADT alone, outcome: 1.1 Time to death due to any cause." data-id="CD013245-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Abiraterone + ADT vs ADT alone, outcome: 1.1 Time to death due to any cause. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 1: Time to death due to any cause" data-id="CD013245-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 1: Time to death due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 2: Quality of life" data-id="CD013245-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 2: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 3: Grades III to V adverse events" data-id="CD013245-fig-0007" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 3: Grades III to V adverse events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 4: Time to death due to prostate cancer" data-id="CD013245-fig-0008" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 4: Time to death due to prostate cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 5: Time to disease progression" data-id="CD013245-fig-0009" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 5: Time to disease progression</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 6: Discontinued treatment due to adverse events" data-id="CD013245-fig-0010" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Abiraterone + ADT vs ADT alone, Outcome 6: Discontinued treatment due to adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: volume of metastases, Outcome 1: Time to death due to any cause" data-id="CD013245-fig-0011" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: volume of metastases, Outcome 1: Time to death due to any cause </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: volume of metastases, Outcome 2: Quality of life" data-id="CD013245-fig-0012" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: volume of metastases, Outcome 2: Quality of life</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: volume of metastases, Outcome 3: Time to death due to prostate cancer" data-id="CD013245-fig-0013" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: volume of metastases, Outcome 3: Time to death due to prostate cancer </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013245-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/urn:x-wiley:14651858:media:CD013245:CD013245-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Subgroup analysis: volume of metastases, Outcome 4: Time to disease progression" data-id="CD013245-fig-0014" src="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_t/tCD013245-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Subgroup analysis: volume of metastases, Outcome 4: Time to disease progression </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/media/CDSR/CD013245/image_n/nCD013245-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013245-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p><b>Patient or population:</b> men with metastatic, hormone‐sensitive prostate cancer<br/><b>Setting:</b> outpatient; multinational sites across UK, Europe, the Asia–Pacific region, Latin America, and Canada<br/><b>Intervention:</b> abiraterone + androgen deprivation therapy (ADT)<br/><b>Comparison:</b> ADT alone </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with ADT only</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with abiraterone + ADT</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to death from any cause</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2201<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.64<br/>(0.56 to 0.73) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>General population<sup>a</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>702 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 fewer per 1000<br/>(210 fewer to 115 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p><i>(Functional Assessment of Cancer Therapy‐prostate [FACT‐P; range 0 to 156; higher values = better quality of life])</i> </p> <p><i>measured at 12 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>838 (1 RCT)</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The mean quality of life for men on ADT only was 116 points</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The MD for men on abiraterone + ADT was 2.9 points higher (0.11 higher to 5.69 higher)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Grades III to V adverse events</b> </p> <p><i>(severe and life threatening, as per the Common Toxicity Criteria v3.0; )</i> </p> <p><i>measured at a median follow‐up of 30 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1199<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>High </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.34<br/>(1.22 to 1.47) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>477 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162 more per 1000<br/>(105 more to 224 more) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to death due to prostate cancer</b> </p> <p><i>measured at a median follow‐up of 30.4 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2201<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.58<br/>(0.50 to 0.68) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120 fewer per 1000<br/>(145 fewer to 90 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Time to disease progression</b> </p> <p><i>measured at a median follow‐up of 30 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>2097<br/>(2 RCTs) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>HR 0.35<br/>(0.26 to 0.49) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>785 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>369 fewer per 1000<br/>(456 fewer to 256 fewer) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Discontinued treatment due to adverse events</b> </p> <p><i>measured at a median follow‐up of 30 months</i> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>1199<br/>(1 RCT) </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>Moderate<sup>d</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50<br/>(1.17 to 1.92) </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p>Study population<sup>c</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101 per 1000</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 more per 1000<br/>(17 more to 93 more) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>HR</b> : hazard ratio; <b>MD</b>: mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p><sup>a</sup>Population data from SEER registry, prostate cancer stage IV 5‐year survival (70.2%) in the pre‐docetaxel era (2007 to 2013)<br/><sup>b</sup>Certainty of evidence graded down by one level due to concerns regarding study limitations related to attrition bias<br/><sup>c</sup>Baseline risk for grades III to V adverse events, prostate cancer‐specific death, and discontinued treatment due to adverse events calculated from the control arm of the LATITUDE trial at a median of 30 months follow‐up (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>)<br/><sup>d</sup>Certainty of evidence downgraded by one level due to study limitations<br/><sup>e</sup>Baseline progression risk calculated from control arm of STAMPEDE trial at 3 years (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>) </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Abiraterone + ADT versus ADT alone in metastatic, hormone‐sensitive prostate cancer</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013245-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of interventions</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions (route, frequency, total dose/day)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comparators (route, frequency, total dose/day)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LATITUDE (<a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone acetate (1000 mg daily, given once daily as four 250 mg tablets) and prednisone (5 mg daily) in addition to ADT, given through either bilateral orchidectomy or luteinizing hormone releasing hormone (LHRH) agonists </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone, given through either bilateral orchidectomy or LHRH agonists</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>STAMPEDE (<a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone (1000 mg) with prednisolone (5 mg), given once daily in addition to ADT, given through LHRH agonists or antagonists, bilateral orchidectomy, combined androgen blockade </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone, given through LHRH agonists or antagonists, bilateral orchidectomy, combined androgen blockade </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>ADT: androgen deprivation therapy; C: comparator; I: intervention</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Description of interventions</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013245-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Intervention and comparator</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Duration of follow‐up</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of participants</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Median age</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Prior local therapy (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Gleason 8 to 10 (%)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013245-bbs2-0001" title="CHiK , ProtheroeA , Rodriguez AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Benefits of abiraterone acetate plus prednisone (AA1P) when added to androgen deprivation therapy (ADT) in LATITUDE on patient (Pt) reported outcomes (PRO). Annals of Oncology2017;28(Suppl 5):v269. CHiK , TranN , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , et al. Subsequent treatment after abiraterone acetate + prednisone (AA + P) in patients (pts) with newly diagnosed high-risk metastatic castration-naïve prostate cancer (NDx-HR mCNPC): detailed analyses from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15 Suppl 1):5028. ChiKN , ProtheroeA , Rodriguez-AntolinA , FacchiniG , SuttmanH , MatsubaraN , et al. Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial. Lancet Oncology2018;19(2):194-206. FeyerabendS , SaadF , PerualilaNJ , Van SandenS , DielsJ , ItoT , et al. Adjusting overall survival estimates for treatment switching in metastatic, castration-sensitive prostate cancer: results from the LATITUDE study. Target Oncology2019;14(6):681-8. [DOI: 0.1007/s11523-019-00685-x]FizaziK , FeyerabendS , MatsubaraN , OzgurogluM , FeinLE , AntolinAT . Longer term preplanned efficacy and safety analysis of abiraterone acetate plus prednisone (AA plus P) in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) from the phase 3 LATITUDE trial. Journal of Clinical Oncology2018;36(15):5028. FizaziK , LarsenJS , MathenyS , MolinaA , LiJ , ToddMB , et al. Randomized double-blind, comparative study of abiraterone acetate (AA) plus low-dose prednisone (P) plus androgen deprivation therapy (ADT) versus ADT alone in newly diagnosed, high-risk, metastatic hormone-naive prostate cancer (mHNPC). Journal of Clinical Oncology2013;31(15 Suppl 1):TPS5097. FizaziK , TranN , FeinL , MatsubaraN , AntolinAR , AlekseevBY , et al. LATITUDE: a phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. Journal of Clinical Oncology2017;35(15 Suppl 1):LBA3. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al, LATITUDE Investigators. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. New England Journal of Medicine2017;377(4):352-60. FizaziK , TranN , FeinL , MatsubaraN , Rodriguez-AntolinA , AlekseevBY , et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncology2019;20(5):686-700. FizaziK , TranN , FeinLE , MatsubaraN , BjartellA , GalliL . Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naive prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial. Journal of Clinical Oncology2018;36(6):182. FukasawaS , SuzukiH , KawaguchiK , NoguchiH , EnjoK , TranN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2018;48(11):1012-21. FukasawaS , SuzukiH , SatoF , HashineK , HasumiH , MatsumotoH . Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial. Journal of Clinical Oncology2018;36(6):1012-21. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Cancer2019;125(4):626-32. LiT , Franco-VillalobosC , ProskorovskyI , SorensenSV , TranN , SulurG , et al. Medical resource utilization of abiraterone acetate plus prednisone added to androgen deprivation therapy in metastatic castration-naive prostate cancer: results from LATITUDE. Journal of Clinical Oncology2018;38(6 Suppl 1):201. MatsubaraN , ChiKN , ÖzgüroğluM , Rodriguez-AntolinA , FeyerabendS , FeinL , et al. Correlation of prostate-specific antigen kinetics with overall survival and radiological progression-free survival in metastatic castration-sensitive prostate cancer treated with abiraterone acetate plus prednisone or placebos added to androgen deprivation therapy: post hoc analysis of phase 3 LATITUDE study. European Urology2020;77(4):494-500. MatsubaraN , ChiKN , OzgurogluM , AntolinAR , FeyerabendS , FeinL , et al. LATITUDE study: PSA response characteristics and correlation with overall survival (OS) and radiological progression-free survival (rPFS) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving ADT plus abiraterone acetate and prednisone (AAP) or placebo (PBO). Annals of Oncology2018;28:271-302. MetinH , McQuarrieK , ThilakarathneP , DielsJ , ItoT , LiT , et al. Benefit of abiraterone acetate plus prednisone (AA+P) added to androgen deprivation therapy (ADT) in patients with high-risk, newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC): post hoc analysis of EQ-5D-5L from the latitude study. Value in Health2018;21 Suppl 1:S38. SuzukiH , ShinT , FukasawaS , HashineK , KitaniS , OhtakeN , et al. Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naive prostate cancer: final subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, phase 3 study. Japanese Journal of Clinical Oncology2020;50(7):810-20. WooH , FizaziK , SulurG , TranN , FeinL , MatsubaraN , et al. Final analysis of phase 3 LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-naive prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT). BJU International2019;123(Suppl 2):27-8. ">Fizazi 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone acetate (1000 mg daily, given once daily as four 250 mg tablets) and prednisone (5 mg daily) in addition to ADT<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>5 years</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>597</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68 years (range 38 to 89)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>602</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 years (range 33 to 92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD013245-bbs2-0002" title='ClinicalTrialsgov. Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy (STAMPEDE). ClinicalTrials.gov2005. HoyleAP , AliA , JamesND , CookA , ParkerCC , deBonoJS , et al. Abiraterone in "high-" and "low-risk" metastatic hormone-sensitive prostate cancer. European Urology2019;76(6):719-28. JamesND , deBonoJS , SpearsMR , ClarkeN , MasonMD , DearnaleyD , et al. Adding abiraterone for men with high-risk prostate cancer (PCa) starting longterm androgen deprivation therapy (ADT): survival results from STAMPEDE (NCT00268476). Journal of Clinical Oncology2017;35(18 Suppl):LBA5003. JamesND , deBonoJS , SpearsMR , ClarkeNW , MasonMD , DearnaleyDP , et al. Abiraterone for prostate cancer not previously treated with hormone therapy. New England Journal of Medicine2017;377(4):338-51. '>James 2017</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I1: abiraterone (1000 mg) with prednisolone (5 mg), given once daily in addition to ADT<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Until<br/>death of<br/>all randomised<br/>men </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>500</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 years (range 42 to 85)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C1: ADT alone<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>502</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67 years (range 39 to 84)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NR</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>NR: not reported<br/>ADT: androgen deprivation therapy<br/>C: comparator; I: intervention; SD: standard deviation </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>The following therapies were classified as ADT: luteinizing hormone releasing hormone agonists or antagonists, bilateral orchidectomy, combined androgen blockade </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/full#CD013245-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013245-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Abiraterone + ADT vs ADT alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Time to death due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.56, 0.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.90 [0.11, 5.69]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Grades III to V adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.34 [1.22, 1.47]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Time to death due to prostate cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.50, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Time to disease progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [0.26, 0.49]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Discontinued treatment due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1199</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [1.17, 1.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Abiraterone + ADT vs ADT alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013245-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: volume of metastases</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Time to death due to any cause <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.63 [0.55, 0.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Low volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.50, 0.91]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 High volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.61 [0.53, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>838</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.45 [‐2.15, 7.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Low volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.03 [‐10.98, 6.92]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 High volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.68 [0.73, 6.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Time to death due to prostate cancer <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.51, 0.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.1 Low volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.44, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3.2 High volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.49, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Time to disease progression <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.36, 0.58]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.1 Low volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.33, 0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.4.2 High volume metastases</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.46 [0.31, 0.69]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Subgroup analysis: volume of metastases</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013245.pub2/references#CD013245-tbl-0005">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013245.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013245-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013245-note-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013245-note-0010">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD013245-note-0008">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD013245-note-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="th#CD013245-note-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD013245-note-0005">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013245\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013245\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013245\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013245\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013245\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=gpg7sF9V&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013245.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013245.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013245.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013245.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013245.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719611323"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013245.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719611327"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013245.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918decfc9f439373',t:'MTc0MDcxOTYxMS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 